Characteristics of agonist displacement of [3H]ketanserin binding to platelet 5-HT2A receptors:: implications for psychiatric research

被引:2
|
作者
Gurguis, GNM [1 ]
Phan, SP
Blakeley, JE
机构
[1] Univ Texas, SW Med Ctr, Dept Psychiat, Dallas, TX 75235 USA
[2] Vet Affairs Med Ctr, Mental Hlth Serv, Dallas, TX 75216 USA
关键词
H-3]ketanserin; human platelets; 5-H-2A; receptors; agonist affinity; coupling efficiency; G(q) protein;
D O I
10.1016/S0165-1781(98)00077-8
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Brain 5-HT2A receptors exist in two agonist affinity states as a function of their coupling to G(q) protein. This has not yet been shown in platelets. We examined [H-3]ketanserin's saturable binding to platelet 5-HT2A receptors and characteristics of agonist displacement curves of [H-3]ketanserin binding in healthy control subjects. [H-3]ketanserin saturation curves showed a trend for a two-site model, reflecting two independent binding sites. At low [H-3]ketanserin concentrations, agonist displacement curves were flat and best fit a two-site model, indicating the existence of two agonist affinity states. Guanylyl 5'-imidotriphosphate [Gpp(NH)p] induced a significant rightward shift in agonist displacement curves to fit a one-site model. Platelet membrane 5-HT2A receptors exist in two agonist affinity states that are regulated by G(q) protein. Platelet 5-HT2A receptors provide an accessible model for examining possible dysregulation in the agonist affinity or coupling efficiency to the phosphoinositide system in psychiatric disorders and their modulation by psychotropic medications. Published by Elsevier Science Ireland Ltd.
引用
收藏
页码:227 / 238
页数:12
相关论文
共 50 条
  • [1] Serotonin displacement of 3H-ketanserin binding to platelet 5-HT2A receptors in normal controls and depressed patients
    Gurguis, GNM
    Phan, SP
    Blakeley, JE
    Dikis, EJ
    Rush, AJ
    [J]. BIOLOGICAL PSYCHIATRY, 1998, 43 : 97S - 98S
  • [2] Effect of fluvoxamine on platelet 5-HT2A receptors as studied by [3H]lysergic acid diethylamide ([3H]LSD) binding in healthy volunteers
    O. Spigset
    Tom Mjörndal
    [J]. Psychopharmacology, 1997, 133 : 39 - 42
  • [3] Genetic variation in the 5-HT2A receptor and altered neocortical [3H] ketanserin binding in Alzheimer's disease
    Holmes, C.
    McCulley, M.
    Nicoll, J. A. R.
    Alder, J. T.
    Chen, C. P. L. -H.
    Francis, P. T.
    [J]. NEUROSCIENCE LETTERS, 2007, 420 (01) : 58 - 60
  • [4] Platelet 3H ketanserin binding in migraine
    Shukla, R
    Khanna, VK
    Pradeep, S
    Husain, M
    Tandon, R
    Nag, D
    Dikshit, M
    Srimal, RC
    Seth, PK
    [J]. CEPHALALGIA, 2001, 21 (05) : 567 - 572
  • [5] Ketanserin binding characteristics to 5-HT2A receptor: Evidence for two binding subsites
    Gurguis, GNM
    Shewmake, K
    Rush, AJ
    [J]. BIOLOGICAL PSYCHIATRY, 1996, 39 (07) : 118 - 118
  • [6] Variations in [3H]imipramine and 5-HT2A but not [3H]paroxetine binding sites in suicide brains
    Rosel, P
    Arranz, B
    Vallejo, J
    Oros, M
    Crespo, JM
    Menchon, JM
    Navarro, MA
    [J]. PSYCHIATRY RESEARCH-NEUROIMAGING, 1998, 82 (03) : 161 - 170
  • [7] Human striosomes are enriched in 5-HT2A receptors:: autoradiographical visualization with [3H]MDL100,907, [125I](±)DOI and [3H]ketanserin
    López-Giménez, JF
    Mengod, G
    Palacios, JM
    Vilaró, MT
    [J]. EUROPEAN JOURNAL OF NEUROSCIENCE, 1999, 11 (10) : 3761 - 3765
  • [8] [3H]-Ketanserin binding sites in different psychiatric disorders
    Marazziti, D
    Giannaccini, G
    Giromella, A
    Betti, L
    Baroni, S
    Masala, I
    Lucacchini, A
    Cassano, GB
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2003, 13 : S459 - S459
  • [9] [3H]-ketanserin binding sites in different psychiatric disorders
    Marazziti, D
    Giannaccini, G
    Giromella, A
    Betti, L
    Pesce, D
    Nardi, I
    Rossi, A
    Lucacchini, A
    Cassano, GB
    [J]. NEUROCHEMISTRY INTERNATIONAL, 2003, 42 (06) : 511 - 516
  • [10] [3H]-ketanserin binding sites in different psychiatric disorders
    Marazziti, D
    Giromella, A
    Di Nasso, E
    Rossi, A
    Masala, I
    Baroni, S
    Giannaccini, C
    Cassano, GB
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2002, 12 : S24 - S24